CDK4 and breast carcinoma: Multiple clinical trials are underway to test triple combinations of antihormonal therapy with HER2 and CDK4/6-targeted agents in locally advanced and metastatic HR+/HER2+ breast cancer, offering new hope to patients with this challenging disease.